A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors

  1. Hanley, M.J.
  2. D'Arcangelo, M.
  3. Felip, E.
  4. Garrido, P.
  5. Zhu, J.
  6. Ye, M.
  7. Vranceanu, F.
  8. Gupta, N.
Revue:
Journal of Clinical Pharmacology

ISSN: 1552-4604,  0091-2700

Année de publication: 2023

Volumen: 63

Número: 5

Pages: 583-592

Type: Article

DOI: 10.1002/JCPH.2198 GOOGLE SCHOLAR lock_openAccès ouvert editor

Objectifs de Développement Durable

La source de données: Scopus